Rivaroxaban induced liver injury: A cholestatic pattern

International Journal of Cardiology

Volumn 216, Issue , 2016, Pages 97-98

  Cordeanu, Mihaela ^a   Gaertner, Sébastien ^a   Bensalah, Naouel ^b   Mirea, Corina ^a   Hamade, Amer ^b   Stephan, Dominique ^a,c  

^a Strasbourg Regional University Hospital   (France)

^b Mulhouses General Hospital   (France)

^c HÔPITAL CIVIL   (France)

Author keywords

Direct oral anticoagulant; Drug induced liver injury; Hepatotoxicity; Rivaroxaban; RUCAM; Venous thromboembolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LOW MOLECULAR WEIGHT HEPARIN; PANTOPRAZOLE; PARACETAMOL; RIVAROXABAN; TRAMADOL;

ADULT; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRANSAMINASEMIA; LETTER; LIVER INJURY; LIVER TOXICITY; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG INFARCTION; MEDICAL HISTORY; PRIORITY JOURNAL; UPPER EXTREMITY DEEP VEIN THROMBOSIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; MIDDLE AGED; PULMONARY EMBOLISM;

CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DISEASE MANAGEMENT; FEMALE; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; RIVAROXABAN;

EID: 84964645534     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.063     Document Type: Article

References (12)

1. M. Keisu, and T.B. Andersson Drug-induced liver injury in humans: the case of ximelagatran Handb. Exp. Pharmacol. 196 2010 407 418
2. A. Lambert, M. Cordeanu, S. Gaertner, S. Nouri, M. Alt, and D. Stephan Rivaroxaban-induced liver injury: results from a venous thromboembolism registry Int. J. Cardiol. 191 2015 265 266
3. P. Barrett, R. Vuppalanchi, H. Masuoka, and N. Chalasani Severe drug-induced skin and liver injury from rivaroxaban Dig. Dis. Sci. 60 6 2015 1856 1858
4. E. Liakoni, A.E. Rätz Bravo, and S. Krähenbühl Hepatotoxicity of new oral anticoagulants (NOACs) Drug Saf. 38 8 2015 711 720
5. European Medicines Agency, 2015. Evaluation of Medicines for Human Use. CHMP Assessment report for Xarelto. Doc.Ref.: EMEA/543519/2008.
6. P.B. Watkins, M. Desai, S.D. Berkowitz, G. Peters, Y. Horsmans, D. Larrey, and W. Maddrey Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery Drug Saf. 34 3 2011 243 252
7. D. Caldeira, M. Barra, A.T. Santos, and et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis Heart 100 7 2014 550 556
8. E. Raschi, E. Poluzzi, A. Koci, and et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system Br. J. Clin. Pharmacol. 80 2 2015 285 293
9. Eudravigilance, Xarelto, February 2016, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/landing/news-and-events.jsp.
10. C.E. Mahan Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment J. Thromb. Thrombolysis 39 3 2015 295 303
11. E. Raschi, and F. De Ponti Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk World J. Hepatol. 7 13 2015 1761 1771
12. G. Danan, and C. Benichou Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries J. Clin. Epidemiol. 46 1993 1323 1330